PerkinElmer and Predictive Diagnostics announce Discovery of Blood Biomarkers for Alzheimer's Disease
PerkinElmer Inc. and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation, announced that they have found a series of biomarkers that appear to differ in persons with Alzheimer's disease compared to persons without cognitive impairment, using a simple blood test.
The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center (Chicago, Illinois), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study.
The blood analysis was carried out using PerkinElmer's BioXPRESSION(tm) Biomarker platform and Predictive Diagnostic's proprietary BAMF(tm) technology to identify patterns of proteins and peptides that distinguish Alzheimer's disease patients from those without clinical signs. The serum samples used in the study were donated by the Rush Alzheimer's Disease Center.
In numerous collaborative studies, Predictive Diagnostics has demonstrated the capability of its BAMF(tm) technology to accurately diagnose cancers such as breast, lung, pancreatic and prostate, as well as multiple sclerosis. Predictive Diagnostics believes its diagnostic tests will provide better patient outcome through early detection of cancer and other serious diseases and significantly reduce the cost of healthcare associated with treatment of such diseases.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.